《新股消息》赤子城科技(09911.HK)公开发售超购逾1,440倍1.68元定价 一手中签率2%
将於明日(31日)挂牌上市的赤子城科技(09911.HK)公布发售价及配发结果,发售价定於每股1.68元,高於其招股价区间1.4元至1.8元之中位数,集资净额料为1.76亿元。民银资本为保荐人。
公开发售部份录得1,441.83倍认购,於回拨机制下,相关部份发售股份增至6,800万股,占是次整体发售之50%。国际发售初步提呈发售的发售股份已获大幅超额认购,每手2,000股,一手中签率2%,认购300手方稳中一手。
假设超额配股权未获行使,基石投资者Huobi Capital及LC Elec将合共认购1,379万股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.